Rituximab allergic reactions include rash, erythema, facial flushing, laryngeal edema, and tachycardia, etc. When allergic reactions occur, the drug should be stopped immediately and active anti-allergic treatment should be given. Rituximab is a human-mouse chimeric monoclonal antibody that specifically binds to CD20 antigen on B cells and induces apoptosis of B cells. It is indicated for the combination therapy of relapsed or drug-resistant follicular central lymphoma, initially untreated CD20-positive stage III-IV follicular lymphoma, and CD20-positive diffuse large B-cell lymphoma. The drug is contraindicated in allergic individuals, pregnant women, patients with a combination of severe infections, severe heart failure, and immunodeficiency. Adverse reactions that are likely to occur during the use of the drug include decreased white blood cell count, chills, fever, gastrointestinal discomfort, palpitations, and dizziness. Patients who are sensitized to rituximab may experience rash, skin erythema, peripheral edema, pharyngeal irritation, facial flushing, tachycardia, hypotension, and other manifestations, and in severe cases, anaphylactic shock or even death may occur. Therefore, vital signs should be closely monitored during administration and anti-allergic pretreatment should be carried out before infusion. When the above symptoms occur, the drug should be stopped immediately, vital signs should be monitored, and symptomatic treatment such as anti-shock and anti-allergy should be given to avoid aggravating the condition and delaying the treatment.